Documentary

Ebola: The 7-Gene Virus, the 2019 Cure, and the 2026 Epidemic

Published
October 20, 2026
Running time
1 h 1 min
Views
29.1K
Medically reviewed by
Dr. Iván Trompa, October 21, 2026

What it's about

A one-hour documentary on fifty years of Ebola (1976 to 2026), from the twin outbreaks at Nzara and Yambuku to the May 2026 Bundibugyo epidemic in Central Africa. It explains how the virus's seven genes disarm human immunity, what actually kills patients at the bedside, how the 2019 PALM trial and the Ervebo vaccine cut mortality for the Zaire species, and why those tools do not cover Bundibugyo ebolavirus. It ends with the funding and governance failures of the 2026 response.

  • The first two Ebola outbreaks appeared in 1976 almost simultaneously in Nzara (Sudan) and Yambuku (Zaire, now the Democratic Republic of the Congo).
  • The virus has only seven genes, yet proteins such as VP35, VP24 and sGP help it disarm the immune system, and it enters cells through the NPC1 receptor.
  • Survivors can carry the virus for years: the 2021 Guinea outbreak arose from a virus that had persisted in a survivor for about five years.
  • At the bedside, cholera-like fluid loss and potassium collapse are described as the real killers, not only bleeding.
  • The 2019 PALM trial and the Ervebo vaccine cut Zaire ebolavirus mortality to about 10 percent, but these tools are specific to that species and do not cover Bundibugyo ebolavirus.
  • The video reports that the May to October 2026 Bundibugyo epidemic reached about 9,000 cases and 4,300 deaths, and that an Africa CDC audit found more than 700 million dollars lost in intermediary chains.

Sources

Corrections

  • Clarification at 14:51. The film says that “a person with no fever and no symptoms cannot transmit Ebola to anyone.” That is correct for the incubation period: someone who has been infected does not spread the virus before they fall ill. It does not apply to people who have already recovered. Ebola virus can persist for months in parts of the body where the immune system acts less, such as the testes, the inside of the eye and the nervous system, and in the breast milk of women infected while breastfeeding (the film returns to this at 19:10). In a cohort of survivors in Sierra Leone, the virus's genetic material was still found in the semen of three in four men at six months and of about 6% at one year. Men who had fully recovered and had no symptoms have transmitted Ebola sexually more than a year after their illness, and entire outbreaks began that way, such as those in Guinea in 2016 and 2021. That is why the WHO advises male survivors to practise safer sex for 12 months from the onset of symptoms, or until two semen tests are negative. None of this justifies stigma: medical follow-up of survivors is part of controlling an epidemic.
  • Clarification at 1:19 (opening) and in the video description. The opening says the two-antibody treatments “slashed mortality down to 10%.” In the PALM trial in the Democratic Republic of the Congo, 28-day mortality was 35.1% with mAb114 (ansuvimab) and 33.5% with REGN-EB3 (Inmazeb), compared with about 50% with ZMapp. Mortality close to 10% was seen only among patients who reached treatment early, with a low viral load, as the film explains at 36:46. Early diagnosis is what makes these drugs work best. Source: Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303. doi:10.1056/NEJMoa1910993.

Keep watching

Arrow keys to move, Enter to open, Esc to close.